By Brendan Borrell

The much-awaited $1,000 genome sequence may never arrive on the market if the owners of patents on disease-related genes have their way. With an estimated 20% of human genes patented, the so-called ‘patent thicket’ could hinder the advancement of diagnostics that rely on multiple genes, genome-wide scans or whole genome sequences. (Click here to continue reading)